A Phase 2 Multi-Center Pharmacodynamic Study Of Tvb-2640 In Kras Mutant Non-Small Cell Lung Carcinomas
Posted Date: Apr 26, 2024
- Investigator: Jennifer Leddon
- Specialties: Cancer, Lung Cancer
- Type of Study: Drug
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
Criteria:
Null
Keywords:
Non Small Cell
For More Information:
Alexis Brenner
NULL
cancer@uchealth.com